Dihydroorotate

Dihydroorotate

SCHEMBL417324

O=C1C[C@@H](C(=O)O)NC(=O)N1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAD P27708 2/20 0.43
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.39
EGLN1 Q9GZT9 1/20 0.38
ITGB3 P05106 1/20 0.38
ITGB2 P05107 1/20 0.38
ITGB1 P05556 1/20 0.38
ITGAV P06756 1/20 0.38
ITGA2B P08514 1/20 0.38
ITGA5 P08648 1/20 0.38
ITGB5 P18084 1/20 0.38
ITGAL P20701 1/20 0.38
CYP2D6 P10635 2/20 0.37
LMNA P02545 2/20 0.37
BLM P54132 2/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dihydroorotate SCHEMBL29901858 1.00 CAD (0.43) CADGAAMAPTHTTEGLN1
Dihydroorotate SCHEMBL121953 1.00 CAD (0.43) CADGAAMAPTHTTEGLN1
Dihydroorotate SCHEMBL758070 1.00 CAD (0.43) CADGAAMAPTHTTEGLN1
Dihydroorotate SCHEMBL20818976 0.85 MAPT (0.38) CADGAAMAPTHTTALDH1A1
SCHEMBL690090 0.84
SCHEMBL690089 0.84
SCHEMBL1300246 0.84
SCHEMBL16467758 0.81 CAD (0.48) CADGAAMAPTHTTEGLN1
SCHEMBL6950284 0.81
SCHEMBL23182639 0.81 CRBN (0.38) CADHTTITGB3ITGB2ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4537111-A2 MULTI-OMICS ASSESSMENT Prognomiq Inc (US) 2025-04-16 EP claimed
CN-117265603-A Galvanized brightening agent composition for ship corrosion prevention and preparation method thereof 姚春雷 2023-12-22 CN claimed
WO-2023240046-A2 MULTI-OMICS ASSESSMENT PrognomIQ, Inc. (US) 2023-12-14 WO claimed
US-20230346831-A1 METHODS FOR TREATING METASTATIC CANCER USING LOW DOSE CARBON MONOXIDE CORNELL UNIVERSITY (US) 2023-11-02 US claimed
WO-2023144235-A1 METHODS FOR MONITORING AND TREATING WARBURG EFFECT IN PATIENTS WITH PI3K-RELATED DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2023-08-03 WO claimed
CN-111289638-A Application of serum metabolism marker in preparation of diabetic nephropathy early diagnosis reagent and kit 浙江大学 2020-06-16 CN claimed
CN-103992392-A Solid-phase synthesis method of degarelix TAIZHOU SHIMEIKANG POLYPEPTIDE DRUG TECHNOLOGY CO LTD 2014-08-20 CN claimed
CN-102864196-B Method for preparing alpha-aspartyl small peptide by dihydroorotic acid enzyme method NANJING UNIVERSITY OF TECHNOLOGY 2014-07-02 CN claimed
US-8494779-B2 Method for screening essential metabolites in growth of microorganisms KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-07-23 US claimed
US-20100143911-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-06-10 US claimed
EP-2097743-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS Korea Advanced Institute of Science and Technology (KR) 2009-09-09 EP claimed
US-20080248493-A1 ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES ABBOTT LABORATORIES 2008-10-09 US claimed
WO-2008078911-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2008-07-03 WO claimed
WO-2005100382-A1 VERTEBRATE PEPTIDE MODULATORS OF LIPID METABOLISM BLM GROUP, INC. (US) 2005-10-27 WO claimed
US-20050222040-A1 Vertebrate peptide modulators of lipid metabolism BLM GROUP, INC. (US) 2005-10-06 US claimed
EP-0673783-B1 Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds XEROX CORP (US) 2000-07-05 EP claimed
EP-4729603-A2 METABOLOMIC CHARACTERIZATION OF MICROORGANISMS Lewis, Ian Andrew (CA) 2026-04-22 EP disclosed
US-20260097019-A1 METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2026-04-09 US disclosed
EP-0673783-A2 Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds XEROX CORPORATION (US) 1995-09-27 EP disclosed
EP-0338499-A2 Stabilized highly unsaturated fatty acids and derivatives of such acids NABISCO BRANDS, INC. (US) 1989-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097019-A1 METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS MALT1, BRDT, BCL6 CAD 4656/4885GAA 2639/4885MAPT 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.